DexCom

YTD

ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

CEO

Jacob S. Leach

CEOJacob S. Leach

Employees

11,100

Employees11,100

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1999

Founded1999

Employees

11,100

Employees11,100

DXCM Key Statistics

Market cap

32.47B

Market cap32.47B

Price-Earnings ratio

32.95

Price-Earnings ratio32.95

Dividend yield

—

Dividend yield—

Average volume

3.51M

Average volume3.51M

High today

$88.87

High today$88.87

Low today

$85.80

Low today$85.80

Open price

$87.78

Open price$87.78

Volume

3.59M

Volume3.59M

52 Week high

$92.59

52 Week high$92.59

52 Week low

$54.11

52 Week low$54.11

Stock Snapshot

As of today, DexCom(DXCM) shares are valued at $85.90. The company's market cap stands at 32.47B, with a P/E ratio of 32.95.

On 2026-10-17, DexCom(DXCM) stock traded between a low of $85.80 and a high of $88.87. Shares are currently priced at $85.90, which is +0.1% above the low and -3.3% below the high.

DexCom(DXCM) shares are trading with a volume of 3.59M, against a daily average of 3.51M.

During the past year, DexCom(DXCM) stock moved between $54.11 at its lowest and $92.59 at its peak.

DXCM News

MarketWatch 1d

DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch

...

Simply Wall St 2d

DexCom Just Drew Fresh Attention, So What Is The Market Weighing?

DexCom (DXCM) just received a rare spotlight in The New England Journal of Medicine, as its CONNECT randomized trial on the G7 continuous glucose monitor for Ty...

Simply Wall St 3d

How G7 Rollout At DexCom Has Changed Its Investment Story

DexCom is progressing with the rollout of its G7 15-day continuous glucose monitoring system and ramping production capacity, while managing pressures from new...

Analyst ratings

84%

of 32 ratings

Buy

84.4%

Hold

15.6%

Sell

More DXCM News

TipRanks 6d

DexCom price target raised to $96 from $90 at BTIG

BTIG raised the firm’s price target on DexCom (DXCM) to $96 from $90 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 resul...

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.